Neurophth, China's first gene therapy company focusing on ophthalmic diseases, announced the completion of nearly 400 million yuan of round C financing.

This round of financing will be used for the internationalization of core products, continuously promote and enrich the company's R&D pipeline projects, and improve the production capacity in international standards. With subsidiaries in Wuhan, Suzhou, Shanghai, and San Diego, Neurophth is committed to discovering and developing gene therapy for patients with genetic diseases worldwide.

Neurophth's core product NR082 (rAAV2-ND4, NFS-01) is the first ophthalmic gene therapy drug approved for the clinical trial in China. The phase 1/2/3 clinical trial was completed in June this year, and the first patient was enrolled for administration. The 8000 square meters independent production base built in line with the international (NMPA, FDA, EMA) GMP standards has been completed in September this year. Neurophth has a high-yield and stable wall sticking and suspension production process, which can meet the needs of commercial production of products with different characteristics and scales.